New Current Report Filed with the SEC Disclosing Receipt of a Notice of Delisting, the Failure to Satisfy a Continued Listing Rule or Standard or the Transfer of a Listing: 8-K – BioPharmX Corp (0001504167) (Filer)

A current report on Form 8-K was just filed with the U.S. Securities & Exchange Commission (SEC) disclosing receipt of a notice of delisting, the failure to satisfy a continued listing rule or standard or the transfer of a listing. Details of the current report are:

8-K – BioPharmX Corp (0001504167) (Filer)
Filed: 2016-07-25 AccNo: 0001104659-16-134121 Size: 26 KB

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Filing Date: 2016-07-25T16:31:08-04:00

This is a breaking news story. You can access the complete current report through the SEC’s Edgar system: